Gilead Sciences Inc
XETRA:GIS
Gilead Sciences Inc
XETRA:GIS
Price:
122.46
EUR
-0.94%
Market Cap:
€152.6B
Relative Value
The Relative Value of one
GIS
stock under the Base Case scenario is
94.78
EUR.
Compared to the current market price of 122.46 EUR,
Gilead Sciences Inc
is
Overvalued by 23%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
GIS
Relative Value
Base Case
94.78
EUR
Overvaluation 23%
Multiples Across Competitors
GIS Competitors Multiples
Gilead Sciences Inc Competitors
Gilead Sciences Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Gilead Sciences Inc
XETRA:GIS
|
175.1B EUR | 6 | 20.6 | 12.9 | 15.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
364.6B USD | 6 | 87.1 | 14.5 | 20.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.6B USD | 5.1 | 24.4 | 14.2 | 14.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.3B USD | 9.7 | 29.4 | 22.2 | 23.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.9B USD | 5.4 | 17.3 | 12.7 | 14.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.7B AUD | 3.1 | 33.9 | 11.2 | 14.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
36.4B EUR | 10.3 | 33.1 | 35.8 | 36.5 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
41.2B USD | 11.1 | 131.4 | 73.5 | 81.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
